Ontology highlight
ABSTRACT: Purpose
U.S. Food and Drug Administration (FDA) recommended telavancin dosing is based on total body weight (TBW) but lacks adjusted regimens for obese subjects with varying renal function. Our aim was to develop a physiologically based pharmacokinetic (PBPK) model of telavancin to design optimized dosing regimens for obese patients with hospital-acquired pneumonia (HAP) and varying renal function.Methods
The PBPK model was verified using clinical pharmacokinetic (PK) data of telavancin in healthy populations with varying renal function and obese populations with normal renal function. Then, the PBPK model was applied to predict the PK in obese HAP patients with renal impairment (RI).Results
The fold error values of PK parameters (AUC, Cmax, Tmax
SUBMITTER: Wu W
PROVIDER: S-EPMC7808764 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature